Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1α variant for local induction of angiogenesis

Diana Trentin, Heike Hall, Sandra Wechsler, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Hypoxia-inducible factor (HIF) constitutes a target in therapeutic angiogenesis. HIF-1α functions as a sensor of hypoxia and induces expression of vascular endothelial growth factor (VEGF), which then induces angiogenesis. To explore the potential of HIF-1α gene therapy in stimulating wound healing, we delivered a gene encoding a stabilized form of HIF-1α, lacking the oxygen-sensitive degradation domain, namely HIF-1αΔODD, by using a previously characterized peptide-based gene delivery vector in fibrin as a surgical matrix. The peptide vector consisted of multiple domains: (i) A cysteine-flanked lysine hexamer provided DNA interactions that were stable extracellularly but destabilized intracellularly after reduction of the formed disulfide bonds. This DNA-binding domain was fused to either (ii) a fibrin-binding peptide for entrapment within the matrix or (iii) a nuclear localization sequence for efficient nuclear targeting. The HIF-1αΔODD gene was expressed and translocated to the nucleus under normoxic conditions, leading to up-regulation of vascular endothelial growth factor (VEGF)-A165 mRNA and protein levels in vitro. When the peptide-DNA nanoparticles entrapped in fibrin matrices were applied to full-thickness dermal wounds in the mouse (10 μg per wound in 30 μl of fibrin), angiogenesis was increased comparably strongly to that induced by VEGF-A165 protein (1.25 μg per wound in 30 μl of fibrin). However, the maturity of the vessels induced by HIF-1αΔODD was significantly higher than that induced by VEGF-A165 protein, as shown by stabilization of the neovessels with smooth muscle. Nonviral, local administration of this potent angiogenesis-inducing gene by using this peptide vector represents a powerful approach in tissue engineering and therapeutic angiogenesis.

Original languageEnglish
Pages (from-to)2506-2511
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number8
DOIs
StatePublished - Feb 21 2006
Externally publishedYes

Fingerprint

Hypoxia-Inducible Factor 1
Fibrin
Vascular Endothelial Growth Factor A
Oxygen
Peptides
Genes
DNA
Wounds and Injuries
Proteins
Tissue Engineering
Disulfides
Genetic Therapy
Wound Healing
Nanoparticles
Lysine
Cysteine
Smooth Muscle
Up-Regulation
Hypoxia
Messenger RNA

Keywords

  • Fibrin
  • Gene delivery
  • Nonviral vector
  • Polycation

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1α variant for local induction of angiogenesis. / Trentin, Diana; Hall, Heike; Wechsler, Sandra; Hubbell, Jeffrey A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 8, 21.02.2006, p. 2506-2511.

Research output: Contribution to journalArticle

@article{8d70c19d855b4946badb8cccc68f4a36,
title = "Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1α variant for local induction of angiogenesis",
abstract = "Hypoxia-inducible factor (HIF) constitutes a target in therapeutic angiogenesis. HIF-1α functions as a sensor of hypoxia and induces expression of vascular endothelial growth factor (VEGF), which then induces angiogenesis. To explore the potential of HIF-1α gene therapy in stimulating wound healing, we delivered a gene encoding a stabilized form of HIF-1α, lacking the oxygen-sensitive degradation domain, namely HIF-1αΔODD, by using a previously characterized peptide-based gene delivery vector in fibrin as a surgical matrix. The peptide vector consisted of multiple domains: (i) A cysteine-flanked lysine hexamer provided DNA interactions that were stable extracellularly but destabilized intracellularly after reduction of the formed disulfide bonds. This DNA-binding domain was fused to either (ii) a fibrin-binding peptide for entrapment within the matrix or (iii) a nuclear localization sequence for efficient nuclear targeting. The HIF-1αΔODD gene was expressed and translocated to the nucleus under normoxic conditions, leading to up-regulation of vascular endothelial growth factor (VEGF)-A165 mRNA and protein levels in vitro. When the peptide-DNA nanoparticles entrapped in fibrin matrices were applied to full-thickness dermal wounds in the mouse (10 μg per wound in 30 μl of fibrin), angiogenesis was increased comparably strongly to that induced by VEGF-A165 protein (1.25 μg per wound in 30 μl of fibrin). However, the maturity of the vessels induced by HIF-1αΔODD was significantly higher than that induced by VEGF-A165 protein, as shown by stabilization of the neovessels with smooth muscle. Nonviral, local administration of this potent angiogenesis-inducing gene by using this peptide vector represents a powerful approach in tissue engineering and therapeutic angiogenesis.",
keywords = "Fibrin, Gene delivery, Nonviral vector, Polycation",
author = "Diana Trentin and Heike Hall and Sandra Wechsler and Hubbell, {Jeffrey A.}",
year = "2006",
month = "2",
day = "21",
doi = "10.1073/pnas.0505964102",
language = "English",
volume = "103",
pages = "2506--2511",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1α variant for local induction of angiogenesis

AU - Trentin, Diana

AU - Hall, Heike

AU - Wechsler, Sandra

AU - Hubbell, Jeffrey A.

PY - 2006/2/21

Y1 - 2006/2/21

N2 - Hypoxia-inducible factor (HIF) constitutes a target in therapeutic angiogenesis. HIF-1α functions as a sensor of hypoxia and induces expression of vascular endothelial growth factor (VEGF), which then induces angiogenesis. To explore the potential of HIF-1α gene therapy in stimulating wound healing, we delivered a gene encoding a stabilized form of HIF-1α, lacking the oxygen-sensitive degradation domain, namely HIF-1αΔODD, by using a previously characterized peptide-based gene delivery vector in fibrin as a surgical matrix. The peptide vector consisted of multiple domains: (i) A cysteine-flanked lysine hexamer provided DNA interactions that were stable extracellularly but destabilized intracellularly after reduction of the formed disulfide bonds. This DNA-binding domain was fused to either (ii) a fibrin-binding peptide for entrapment within the matrix or (iii) a nuclear localization sequence for efficient nuclear targeting. The HIF-1αΔODD gene was expressed and translocated to the nucleus under normoxic conditions, leading to up-regulation of vascular endothelial growth factor (VEGF)-A165 mRNA and protein levels in vitro. When the peptide-DNA nanoparticles entrapped in fibrin matrices were applied to full-thickness dermal wounds in the mouse (10 μg per wound in 30 μl of fibrin), angiogenesis was increased comparably strongly to that induced by VEGF-A165 protein (1.25 μg per wound in 30 μl of fibrin). However, the maturity of the vessels induced by HIF-1αΔODD was significantly higher than that induced by VEGF-A165 protein, as shown by stabilization of the neovessels with smooth muscle. Nonviral, local administration of this potent angiogenesis-inducing gene by using this peptide vector represents a powerful approach in tissue engineering and therapeutic angiogenesis.

AB - Hypoxia-inducible factor (HIF) constitutes a target in therapeutic angiogenesis. HIF-1α functions as a sensor of hypoxia and induces expression of vascular endothelial growth factor (VEGF), which then induces angiogenesis. To explore the potential of HIF-1α gene therapy in stimulating wound healing, we delivered a gene encoding a stabilized form of HIF-1α, lacking the oxygen-sensitive degradation domain, namely HIF-1αΔODD, by using a previously characterized peptide-based gene delivery vector in fibrin as a surgical matrix. The peptide vector consisted of multiple domains: (i) A cysteine-flanked lysine hexamer provided DNA interactions that were stable extracellularly but destabilized intracellularly after reduction of the formed disulfide bonds. This DNA-binding domain was fused to either (ii) a fibrin-binding peptide for entrapment within the matrix or (iii) a nuclear localization sequence for efficient nuclear targeting. The HIF-1αΔODD gene was expressed and translocated to the nucleus under normoxic conditions, leading to up-regulation of vascular endothelial growth factor (VEGF)-A165 mRNA and protein levels in vitro. When the peptide-DNA nanoparticles entrapped in fibrin matrices were applied to full-thickness dermal wounds in the mouse (10 μg per wound in 30 μl of fibrin), angiogenesis was increased comparably strongly to that induced by VEGF-A165 protein (1.25 μg per wound in 30 μl of fibrin). However, the maturity of the vessels induced by HIF-1αΔODD was significantly higher than that induced by VEGF-A165 protein, as shown by stabilization of the neovessels with smooth muscle. Nonviral, local administration of this potent angiogenesis-inducing gene by using this peptide vector represents a powerful approach in tissue engineering and therapeutic angiogenesis.

KW - Fibrin

KW - Gene delivery

KW - Nonviral vector

KW - Polycation

UR - http://www.scopus.com/inward/record.url?scp=33644533818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644533818&partnerID=8YFLogxK

U2 - 10.1073/pnas.0505964102

DO - 10.1073/pnas.0505964102

M3 - Article

VL - 103

SP - 2506

EP - 2511

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -